Josh Pappas’ Post

Effectiveness of de-implementation of low-value healthcare practices >> "... change infrastructure and workflow and develop stakeholder interrelationships emerged as the most encouraging avenues." https://lnkd.in/ei-W6atr

Check out this article from Outsourcing-Pharma on how Marwan Fathallah is transforming DIA and hoping to revolutionize global healthcare!

A successful digital transformation is a collaborative effort. This includes healthcare payers and providers, governments, pharma companies, academic centers, and private practices. These stakeholders can ensure that the digital systems being implemented tackle the major issues of the field, from treating complex diseases to bolstering operational efficiency. #HealthTech #IT #DigitalTransformation #Healthcare

ZS’s #FutureofHealth Report revealed that German patients want more preventive care, faster access to specialists, higher levels of partnerships with physicians and more convenient and equitable care. We brought together three ZS leaders in the EU to discuss how pharma companies can help patients and providers bridge some of those gaps. #futureofhealth #patientcentricity https://lnkd.in/efGtnv_2

Had a great time speaking at Pharma 4.0 Summit in Munich!  Thanks Bernard Gauthier, Sören Fritsche and Gabriel Bohl for the insightful discussion on Pharma’s role to increase crisis resilience of healthcare delivery. 💡 My Key Takeaways are: 1️⃣ Global GP Shortage - Patients and Pharma are both at risk: Disruption of prescription rates and medication adherence negatively affect patients and pose a risk to Pharma core product revenue. 2️⃣ Digital Health could make the Difference: Connecting Pharma products to suitable digital health solutions could be decisive for patient outcomes and commercial success; examples include companion apps to avoid adherence reduction, AI-based clinical decision support and diagnostics to guide prescriptions decisions. 3️⃣ Feasible Strategies yet have to be developed: Pharma has not yet achieved significant strategic impact with digital health (despite case-base successes); companies need to build up competencies to address current uncertainties in user adoption, reimbursement and integration to health systems. 4️⃣ Digital Pharma Communication can bridge potential loss of personal touchpoints in crises; key impact lever is real-time delivery of easy-to-understand and validated content. 5️⃣ Decentralised Clinical Trials increase R&D resilience; significant learning curve during COVID19 pandemic for Pharma and regulators provide momentum to establish DCTs as standard practice. On a scientific note, I personally found the work of Dr. Ingo Gorr and his colleagues from Boehringer Ingelheim on Oncolytic Viruses especially exciting! Thanks Conferenzia World for the invitation, looking forward to the next event.

**Harnessing Real World Evidence (RWE) and Real World Data (RWD) for Enhanced Access and Economic Efficiency in Healthcare** In today's rapidly evolving healthcare landscape, the integration of Real World Evidence (RWE) and Real World Data (RWD) is revolutionizing how we approach access to medications and economic sustainability. **Accelerating Access to Innovations**: By leveraging RWE and RWD, we can expedite the approval process for new treatments, ensuring that life-saving innovations reach patients faster, especially in areas with unmet medical needs. **Efficiency in Approval Processes**: These real-world insights complement traditional clinical trials, providing additional evidence on the efficacy and safety of medications. This can streamline approval processes, reducing time and costs. **Evidence-Based Decision Making**: Regulatory bodies and policymakers can make more informed decisions regarding the approval and reimbursement of medications, ensuring that healthcare resources are allocated to treatments that truly benefit patients. **Cost-Effectiveness**: Analyzing real-world data helps identify the most cost-effective treatments, balancing clinical benefits with economic considerations. This is crucial for maintaining the sustainability of healthcare systems. **Continuous Monitoring and Adjustments**: Post-approval, RWE and RWD enable ongoing monitoring of a medication's performance in clinical practice, allowing for timely adjustments in usage and reimbursement policies. **Personalized Treatment Approaches**: Real-world data can highlight which patient subgroups respond best to specific treatments, facilitating personalized healthcare and optimizing outcomes. **Economic Impact**: Integrating RWE and RWD can significantly reduce the costs associated with clinical trials and avoid unnecessary expenditures on ineffective treatments, ultimately leading to more affordable medications. Incorporating RWE and RWD into healthcare policies is not just a step forward in medical innovation but a strategic move towards a more efficient, effective, and patient-centric healthcare system.

The healthcare industry is increasingly focused on patient-centricity. From personalised medicine to regulatory shifts, there’s a growing recognition that effective solutions come from understanding the patient’s perspective. Our recent blog uncovers more about the growing importance of patient-centricity in market research, the factors driving the rise, the evolving role of market research in capturing patient insights, and the key challenges and opportunities in creating more patient-focused healthcare solutions. 🔗 Read the full blog > https://hubs.ly/Q02QMdps0 #PatientCentricity #Healthcare #MarketResearch #PersonalisedMedicine #PatientEngagement

Exciting possibilities lie ahead as the AI revolution is set to reshape healthcare; making it predictive, preventive, and personalised. Connected care offers transformative benefits, forging new partnerships and reshaping the industry's dynamics. Yet the blueprint to orchestrate these technology building blocks for greater innovation in care, is still in progress. In a global survey conducted by us, 375 senior decision-makers across healthcare sub-sectors shared insights on the impact of connected care. The survey spanned across North America (40%), Europe (40%), and other geographies (20%), drawing participants from healthcare providers, payers, pharmacies, pharmaceutical manufacturers, and medtech providers. Our research report delves into the nuances of this exciting shift, painting a picture of a healthcare future where all stakeholders have a hand in its reinvention. The change is imminent, and we all have a role in reshaping healthcare for a better tomorrow. Find out more: https://lnkd.in/gUM_WfmD #Healthcare

If #scaling within a single #healthsystem is hard, scaling across #healthcare regions and nations, even across national borders, seems impossible: and that's where A.Catalyst, AstraZeneca's #healthinnovationnetwork, specialises. https://lnkd.in/e37d8zQy

As patients increasingly take control over their health through direct-to-consumer channels, traditional dynamics between patients and healthcare systems are being redefined, leading to a more patient-centric approach in medical delivery and care. This shift could drive significant advancements in accessibility and convenience in healthcare, potentially transforming how medical services are delivered and experienced moving forward. #Healthcare #PatientCare #HealthcareAccess